Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.
BioGaia AB, Eslöv, Sweden.
PLoS One. 2024 Nov 1;19(11):e0312464. doi: 10.1371/journal.pone.0312464. eCollection 2024.
An increased intestinal permeability is a common feature in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Probiotics have shown to improve IBS symptoms and might also affect intestinal barrier function.
The aim of this study was to investigate the effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone (single strain) or in combination with Limosilactobacillus reuteri DSM 17938 (dual strain) on gut barrier function, immune markers, and symptoms in IBS-D patients (ClinicalTrials.gov registration number: NCT03986476).
65 IBS-D patients were randomised into three groups (placebo, single strain, dual strain). Small and large intestinal permeability were assessed using a multi-sugar urinary recovery test. Blood, saliva, faecal samples, and several symptom scales were collected before, and after three and six weeks of intervention.
Small and large intestinal permeability as well as other markers of gut barrier function were not significantly affected by the probiotic interventions. Serum IL-6 levels showed a tendency to be reduced in the single strain group (descriptive p = 0.052). In addition, high-sensitivity C-reactive protein was significantly reduced in the dual strain group (p = 0.041). The participants in both treatment groups reported less gastrointestinal symptoms after three weeks, but this reached significance only in the dual strain group (total score: p = 0.032, pain subscore: p = 0.028). After six weeks, none of the assessed symptoms were significantly different from the placebo.
The probiotic compounds investigated in this study did not seem to affect IBS-D patients' gut barrier function, but showed potential anti-inflammatory and symptom-improving properties, which need to be confirmed in larger study cohorts.
肠通透性增加是腹泻型肠易激综合征（IBS-D）患者的常见特征。益生菌已被证明可改善 IBS 症状，并且可能还会影响肠道屏障功能。
本研究旨在研究单独使用雷氏乳杆菌 ATCC PTA 6475（单一菌株）或与雷氏乳杆菌 DSM 17938（双菌株）联合使用 6 周对 IBS-D 患者肠道屏障功能、免疫标志物和症状的影响（ClinicalTrials.gov 注册号：NCT03986476）。
将 65 名 IBS-D 患者随机分为三组（安慰剂、单一菌株、双菌株）。使用多糖尿回收试验评估小肠和大肠通透性。在干预前、干预后 3 周和 6 周收集血液、唾液、粪便样本和几种症状量表。
益生菌干预对小肠和大肠通透性以及其他肠道屏障功能标志物没有显著影响。单一菌株组的血清 IL-6 水平有降低的趋势（描述性 p = 0.052）。此外，双菌株组的高敏 C 反应蛋白显著降低（p = 0.041）。两组患者在干预 3 周后报告胃肠道症状减少，但仅在双菌株组中达到显著水平（总评分：p = 0.032，疼痛评分：p = 0.028）。干预 6 周后，与安慰剂相比，没有任何评估的症状有显著差异。
本研究中研究的益生菌化合物似乎不会影响 IBS-D 患者的肠道屏障功能，但显示出潜在的抗炎和改善症状的特性，这需要在更大的研究队列中得到证实。
